Send to

Choose Destination
Eur Heart J. 2015 Sep 21;36(36):2438-45. doi: 10.1093/eurheartj/ehv289. Epub 2015 Jul 4.

Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.

Author information

Department of Ambulatory Care and Community Medicine, University of Lausanne, Rue du Bugnon 44, Lausanne CH-1011, Switzerland
Division of Cardiology, Geneva University Hospitals, Geneva, Switzerland.
Department of Ambulatory Care and Community Medicine, University of Lausanne, Rue du Bugnon 44, Lausanne CH-1011, Switzerland.
Department of Cardiology, University Hospital Bern, Bern, Switzerland.
Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
Department of Clinical Research, Institute of Social and Preventive Medicine and Clinical Trials Unit, University of Bern, Bern, Switzerland.
Department of General Internal Medicine, University Hospital of Bern, Bern, Switzerland.



We aimed to assess the prevalence and management of clinical familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS).


We studied 4778 patients with ACS from a multi-centre cohort study in Switzerland. Based on personal and familial history of premature cardiovascular disease and LDL-cholesterol levels, two validated algorithms for diagnosis of clinical FH were used: the Dutch Lipid Clinic Network algorithm to assess possible (score 3-5 points) or probable/definite FH (>5 points), and the Simon Broome Register algorithm to assess possible FH. At the time of hospitalization for ACS, 1.6% had probable/definite FH [95% confidence interval (CI) 1.3-2.0%, n = 78] and 17.8% possible FH (95% CI 16.8-18.9%, n = 852), respectively, according to the Dutch Lipid Clinic algorithm. The Simon Broome algorithm identified 5.4% (95% CI 4.8-6.1%, n = 259) patients with possible FH. Among 1451 young patients with premature ACS, the Dutch Lipid Clinic algorithm identified 70 (4.8%, 95% CI 3.8-6.1%) patients with probable/definite FH, and 684 (47.1%, 95% CI 44.6-49.7%) patients had possible FH. Excluding patients with secondary causes of dyslipidaemia such as alcohol consumption, acute renal failure, or hyperglycaemia did not change prevalence. One year after ACS, among 69 survivors with probable/definite FH and available follow-up information, 64.7% were using high-dose statins, 69.0% had decreased LDL-cholesterol from at least 50, and 4.6% had LDL-cholesterol ≤1.8 mmol/L.


A phenotypic diagnosis of possible FH is common in patients hospitalized with ACS, particularly among those with premature ACS. Optimizing long-term lipid treatment of patients with FH after ACS is required.


Familial hypercholesterolaemia; acute coronary syndrome; cardiovascular prevention; premature atherosclerosis; quality of care

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Zurich Open Access Repository and Archive
Loading ...
Support Center